Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos in Antiviral Discovery Collaboration with Boehringer Ingelheim

NEW YORK, Nov. 11 (GenomeWeb News) - Galapagos Genomics said today that it has entered into a collaboration with Boehringer Ingelheim in the field of antiviral discovery research.

Boehringer Ingelheim will use Galapagos' SilenceSelect platform - a collection of adenoviruses with siRNA-based knockdown sequences targeting over 4,000 human genes -- to perform a genome-wide screen for all drugable genes that influence viral replication in human cells, Galapagos said.

Galapagos said it will receive up-front technology access fees and will be eligible for further license fees during the program. Further financial terms were not disclosed.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.